Description

Tiplimotide (NBI-5788) is an altered peptide ligand (APL) designed from an immunodominant region (83-99) of the neuroantigen myelin basic protein (MBP). Tiplimotide can selectively reduce the production of inflammatory cytokines by pathogenic T-cells. Tiplimotide can be used for the research of multiple sclerosis (MS)[1][2].—COVID-19-immunoregulation–C87H142N24O21—-[1]P D Crowe, et al. NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol. 2000 Nov;48(5):758-65.|[2]Maria Katsara, et al. A double mutation of MBP(83-99) peptide induces IL-4 responses and antagonizes IFN-gamma responses. J Neuroimmunol. 2008 Aug 30;200(1-2):77-89. –178823-49-9–1860.21—-O=C([C@H]1N(CCC1)C([C@@H](NC([C@H](N)C)=O)CCCCN)=O)N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CC2=CN=CN2)C(N[C@@H](CC(C)C)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C(C)C)C(N[C@@H]([C@H](O)C)C(N4[C@@H](CCC4)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@H](O)C)C(N5[C@@H](CCC5)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Inflammation/Immunology; Neurological Disease–10 mM in DMSO–Others—-Others–Peptides